ERBB2 and breast cancer: However, as with the results of other studies, the results of this retrospective analysis showed that the clinical case characteristics and efficacy of NAC in HER2-low differ from those in HER2-zero patients, and it is not possible to clarify the clinicopathological and prognostic characteristics of patients with HER2-low HR-negative BC with this study alone.